| Literature DB >> 29915708 |
Yongda Zhao1, Qin Wang1, Jie Li1, Xiaohuan Lin1, Xianhui Huang1, Binghu Fang1.
Abstract
BACKGROUND: Haemophilus parasuis is a commensal organism of the upper respiratory tract of healthy pigs and causes high morbidity and mortality in piglets. The aim of this study was to investigate the epidemiology of H. parasuis in China from 2014 to 2017.Entities:
Keywords: Antimicrobial susceptibility; Biofilm formation; ERIC-PCR; Haemophilus parasuis; Serotype
Year: 2018 PMID: 29915708 PMCID: PMC6004116 DOI: 10.7717/peerj.5040
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Isolation time and region of 143 H. parasuis isolates.
| Year | Number | Ratio (%) | Region of China | |||||
|---|---|---|---|---|---|---|---|---|
| Northeast | North | East | Central | South | Southwest | |||
| 2014 | 26 | 18.18 | 1 | 1 | 9 | 4 | 9 | 2 |
| 2015 | 47 | 32.87 | 5 | 5 | 19 | 4 | 14 | 0 |
| 2016 | 51 | 35.66 | 6 | 7 | 13 | 5 | 19 | 1 |
| 2017 | 19 | 13.29 | 0 | 3 | 6 | 4 | 6 | 0 |
Note:
Number of strains of H. parasuis isolates from different region of different year from 2014 to 2017.
Figure 1Region distribution of 143 H. parasuis strains in China from 2014 to 2017.
Distribution of different time and region of H. parasuis in northeast, north, east, central, south, and southwest China.
Serotype distribution of 143 H. parasuis isolates for different region.
| Serotype | Different region of China ( | Total | Percent (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Northeast | North | East | Central | South | Southwest | |||
| 1 | 1 | 2 | 3 | 6 | 4.2 | |||
| 2 | 2 | 2 | 1.4 | |||||
| 3 | 2 | 1 | 3 | 2.1 | ||||
| 4 | 3 | 10 | 4 | 15 | 32 | 22.4 | ||
| 5 | 3 | 5 | 13 | 6 | 11 | 38 | 26.6 | |
| 6 | 1 | 2 | 1 | 1 | 5 | 3.5 | ||
| 7 | 2 | 2 | 4 | 1 | 3 | 1 | 13 | 9.1 |
| 8 | 1 | 1 | 2 | 1.4 | ||||
| 9 | 1 | 1 | 0.7 | |||||
| 10 | 1 | 1 | 2 | 1.4 | ||||
| 11 | 1 | 1 | 2 | 1.4 | ||||
| 12 | 1 | 1 | 2 | 3 | 1 | 8 | 5.6 | |
| 13 | 1 | 1 | 4 | 3 | 9 | 6.3 | ||
| 14 | 1 | 2 | 1 | 2 | 6 | 4.2 | ||
| 15 | 1 | 1 | 2 | 1.4 | ||||
| NT | 3 | 3 | 2 | 4 | 12 | 8.4 | ||
| Total | 12 | 16 | 47 | 17 | 48 | 3 | 143 | 1 |
| Percent(%) | 8.4 | 11.2 | 32.9 | 11.9 | 33.6 | 2.1 | 1 | / |
Note:
The percent in the last line is calculated as different region. The percent in the right side column is calculated as different serovars.
Figure 2The epidemic trend of the major serotypes from 2014 to 2017.
Antimicrobial susceptibility of 143 H. parasuis isolates from China 2014 to 2017.
| Antimicrobials | Number of | MIC50 (μg/mL) | MIC90 (μg/mL) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <0.25 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | >512 | |||
| Amoxicillin | 0 | 61 | 17 | 22 | 8 | 5 | 4 | 14 | 4 | 6 | 2 | 0 | 0 | 0 | 0.5 | 16 |
| Ampicillin | 1 | 3 | 47 | 30 | 18 | 9 | 7 | 8 | 2 | 4 | 0 | 3 | 7 | 4 | 1 | 256 |
| Cephalexin | 0 | 1 | 3 | 9 | 11 | 33 | 41 | 20 | 13 | 5 | 3 | 0 | 2 | 2 | 8 | 32 |
| Cefepime | 60 | 0 | 35 | 26 | 14 | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 3 | 0.5 | 2 |
| Ceftiofur | 22 | 52 | 39 | 12 | 4 | 4 | 3 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 0.25 | 4 |
| Ciprofloxacin | 2 | 16 | 23 | 23 | 20 | 18 | 23 | 12 | 4 | 1 | 0 | 0 | 0 | 1 | 2 | 16 |
| Doxycycline | 0 | 10 | 50 | 43 | 16 | 5 | 6 | 2 | 4 | 1 | 1 | 0 | 4 | 1 | 1 | 8 |
| Enrofloxacin | 10 | 5 | 25 | 23 | 24 | 19 | 19 | 11 | 7 | 0 | 0 | 0 | 0 | 0 | 2 | 16 |
| Florfenicol | 0 | 6 | 29 | 41 | 23 | 14 | 10 | 7 | 5 | 0 | 3 | 2 | 2 | 1 | 1 | 16 |
| Gamithromycin | 0 | 4 | 45 | 8 | 6 | 6 | 3 | 8 | 5 | 17 | 1 | 18 | 16 | 6 | 8 | 512 |
| Gentamicin | 1 | 0 | 0 | 8 | 25 | 30 | 32 | 21 | 11 | 3 | 2 | 1 | 5 | 4 | 8 | 64 |
| Kanamycin | 0 | 0 | 1 | 0 | 5 | 11 | 37 | 37 | 17 | 11 | 2 | 4 | 6 | 12 | 16 | 512 |
| Lincomycin | 0 | 1 | 1 | 6 | 10 | 32 | 33 | 25 | 11 | 5 | 5 | 2 | 6 | 6 | 8 | 256 |
| Lomefloxacin | 10 | 3 | 19 | 35 | 17 | 18 | 12 | 13 | 6 | 8 | 2 | 0 | 0 | 0 | 2 | 32 |
| Oxacillin | 0 | 5 | 13 | 8 | 29 | 20 | 25 | 21 | 3 | 3 | 5 | 1 | 5 | 5 | 4 | 128 |
| Polymyxin B | 0 | 50 | 49 | 21 | 1 | 2 | 2 | 3 | 0 | 4 | 1 | 2 | 5 | 3 | 0.5 | 64 |
| Penicillin | 0 | 10 | 52 | 27 | 19 | 7 | 1 | 4 | 7 | 2 | 0 | 5 | 0 | 9 | 1 | 256 |
| Spectinomycin | 0 | 11 | 9 | 18 | 20 | 16 | 20 | 21 | 15 | 4 | 2 | 2 | 3 | 2 | 4 | 32 |
| Tulathromycin | 0 | 1 | 9 | 23 | 24 | 26 | 24 | 9 | 11 | 6 | 2 | 0 | 3 | 5 | 4 | 64 |
| Tildipirosin | 0 | 11 | 34 | 30 | 22 | 10 | 9 | 4 | 4 | 1 | 0 | 1 | 10 | 7 | 1 | 512 |
| Tetracycline | 3 | 15 | 20 | 17 | 13 | 16 | 19 | 14 | 17 | 4 | 2 | 2 | 0 | 1 | 4 | 32 |
| Tilmicosin | 0 | 1 | 6 | 13 | 27 | 27 | 28 | 8 | 13 | 8 | 3 | 1 | 3 | 5 | 4 | 64 |
Note:
No CLSI breakpoints or other references available.
H. parasuis strains with differing biofilm profiles and virulent characteristics.
| Biofilm-forming ability | Number of isolates | Involving serotypes | Virulent characteristics | ||
|---|---|---|---|---|---|
| High | Moderate | Non-virulent | |||
| Strong | 16 | 4,5,7,10,12,13, NT | 10 | 3 | 2 |
| Moderate | 24 | 4,5,6,7,8,13,15, NT | 10 | 8 | 5 |
| Weak | 59 | 1,2,3,4,5,6,7,9,11,12,13,14, NT | 30 | 14 | 10 |
| Absent | 44 | 1,2,3,4,5,6,7,8,19,12,13,14, NT | 20 | 11 | 9 |
Notes:
Highly virulent; 1, 5, 10, 12, 13, 14 serotype; moderately virulent: 2, 4, 15 serotype; Non-virulent; 3, 6, 7, 8, 9, 11 serotype. Serovars used as an indicator of virulence are according to Oliveira & Pijoan (2004). The NT (non-typeable) were not divided into highly, moderately or nonvirulent.
Figure 3ERIC-PCR dendrogram of 99 H. parasuis field isolates.
Antimicrobial susceptibility of H. parasuis for biofilm positive isolates and biofilm negative isolates.
| Antimicrobials | Biofilm positive isolates ( | Biofilm negative isolates ( |
|---|---|---|
| Range of MIC (μg/mL) | Range of MIC (μg/mL) | |
| Amoxicillin | 0.25–64 | 0.25–16 |
| Ampicillin | <0.25–>512 | 0.25–>512 |
| Cephalexin | 0.25–>512 | 1–128 |
| Cefepime | <0.25–>512 | <0.25–16 |
| Ceftiofur | <0.25–>512 | <0.25–8 |
| Ciprofloxacin | <0.25–>512 | 0.25–16 |
| Doxycycline | 0.25–>512 | 0.25–32 |
| Enrofloxacin | <0.25–32 | <0.25–32 |
| Florfenicol | 0.25–>512 | 0.25–128 |
| Gamithromycin | 0.25–>512 | 0.5–>512 |
| Gentamicin | <0.25–>512 | 1–512 |
| Kanamycin | 0.5–>512 | 2–512 |
| Lincomycin | 0.5–>512 | 0.25–>512 |
| Lomefloxacin | <0.25–64 | <0.25–64 |
| Oxacillin | 0.25–>512 | 0.25–>512 |
| Polymyxin B | 0.25–>512 | 0.25–512 |
| Penicillin | 0.25–>512 | 0.25–>512 |
| Spectinomycin | 0.25–>512 | 0.25–256 |
| Tulathromycin | 0.5–>512 | 0.25–>512 |
| Tildipirosin | 0.25–>512 | 0.25–>512 |
| Tetracycline | <0.25–>512 | 0.25–256 |
| Tilmicosin | 0.5–>512 | 0.25–>128 |
| Trimethoprim/sulfamethoxazole | 0.5–>512 | 0.5–>512 |